Case Report on Leiomyosarcoma of the Vulva: A Rare Pathology

Authors

Samantha A. Smith, Marshall University, Joan C. Edwards School of MedicineFollow
Nadim Bou Zgheib, Marshall University Joan C. Edwards School of MedicineFollow
Andrea M. Vallejos, Valley Health Systems OB/GYN - Huntington, WV
Jonathan D. Cuda, Marshall University Joan C. Edwards School of MedicineFollow

Author Credentials

Samantha A. Smith BS Nadim Bou Zgheib MD, FACOG Andrea M. Vallejos MD Jonathan D. Cuda MD

Author ORCID Identifier

https://orcid.org/0000-0001-8716-3264

Keywords

Leiomyosarcoma; Vulva; Immunohistochemical

Disciplines

Medical Pathology | Medical Sciences | Medicine and Health Sciences | Obstetrics and Gynecology | Oncology

Abstract

Leiomyosarcoma (LMS) of the vulva is rare. However it is the most common histologic subtype of vulvar sarcoma, accounting for approximately 1% of all vulvar malignancies. ^[1-8] Whether genetics and epigenetics play a role in pathogenesis is unclear. ^[1] The tumor is slow-growing with non-specific symptoms, has high metastatic potential, and follows a bimodal age distribution. ^[1-8] Diagnosis and prognosis are based upon immunohistochemical expression and criteria from early literature. ^[1,3,5-7] The most common therapeutic approach involves radical vulvectomy with lymph node resection. The value of adjuvant chemotherapy and radiation remains unknown. ^[1,3,5-8] Our case describes a 46-year-old Caucasian G2P2 female with LMS of the left labia.

Recommended Citation

Smith SA, Bou Zgheib N, Vallejos AM, Cuda JD. Case Report on Leiomyosarcoma of the Vulva: A Rare Pathology. Marshall J Med. 2020; 6(3): 20 DOI: https://doi.org/10.33470/2379-9536.1294.